The Liver Meeting 2022-Liver Cancer SIG and Pediatric Liver Disorders SIG Program: Pediatric Liver Cancers: From Mechanisms to Treatment. PART 2: Improving Treatment

Liver Cancer SIG and Pediatric Liver Disorders SIG Program: Pediatric Liver Cancers: From Mechanisms to Treatment. PART 2: Improving Treatment

Back to course

Video Transcription

Video Summary

The panel discussion on pediatric liver cancer highlighted the challenges of relapse and resistance in treatment. The goal for cure involves eradicating all disease sites through systemic therapy and local control. Cisplatin and doxorubicin are the main therapies used, with other drugs like ifosfamide and carboplatin showing some success in treating relapsed patients. However, many treatments have been disappointing, and the development of new therapies and clinical trials is crucial. Current trials are investigating immunotherapy, targeted therapy, and combination therapies. Collaboration and a multidisciplinary approach are emphasized in studying and treating pediatric liver cancer. Understanding the molecular characteristics and subtypes of the disease is also important. The panelists discussed patient-centered communication and involving parents and patients in decision-making. The ongoing FIT trial, focusing on molecular analysis and targeted therapies, was highlighted as an important effort in advancing treatment. Continued efforts to improve outcomes for pediatric liver cancer patients are needed, and patient advocacy plays a crucial role in achieving this goal.

Asset Caption

This joint SIG Program is developed in collaboration by the Liver Cancer and Pediatric Liver Disorders SIGs in an effort to highlight state of the art research eludicating multiple pathways of the paticcarcinogenesis and how these findings have informed the selection of established and emerging medical therapies. Highlighting the program will be lectures on molecular and subtypes of pediatric liver tumors and their correlation with clinicohistopathologic features, mechanisms of treatment resistance in hepatoblastoma, current clinical guidelines in the treatment of pediatric liver cancer, novel therapeutic targets and patient/family priorities in their clinical care.

Keywords

pediatric liver cancer

relapse

resistance

systemic therapy

local control

Cisplatin

doxorubicin

ifosfamide

carboplatin

new therapies

clinical trials

immunotherapy

targeted therapy